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Abstract  
Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite 
substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could 
combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-
dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral 
replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae 
antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against 
hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship 
enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV 
NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and murine 
norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp 
Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, 
Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp 
inhibition range: IC50 4.3–16.6 µM), TMC-647055 (IC50 range: 18.8–45.4 µM) and Beclabuvir 
(IC50 range: 23.8–>100 µM). In silico studies and site-directed mutagenesis indicated the JTK-
109 binding site was within the calicivirus RdRp thumb domain, in a pocket termed Site-B, 
which is highly-conserved within all calicivirus RdRps. Additionally, RdRp inhibition assays 
revealed that JTK-109 was antagonistic with the previously reported RdRp inhibitor pyridoxal-
ϱ′-phosphate-6-;Ϯ′-naphthylazo-ϲ′-nitro-ϰ′,8′-disulfonate) tetrasodium salt (PPNDS), that also 
binds to Site-B. Moreover, like JTK-109, PPNDS was also a potent inhibitor of polymerases 
from six viruses spanning the three Caliciviridae genera tested (IC50 range: 0.1–2.3 µM). 
Together, this study demonstrates the potential for de novo development of broad-spectrum 
antivirals that target the highly-conserved RdRp thumb pocket, Site-B. We also revealed three 
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broad-spectrum HCV NNIs that could be used as antiviral scaffolds for further development 
against caliciviruses and other viruses.  
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1 Introduction  
There is currently a lack of both narrow and broad-spectrum antivirals (BS-AVs) available to 
combat viral pathogens (1). This deficiency of BS-AVs is due to the complexity of viral 
replication strategies and their various host tropisms (2). Antivirals are generally targeted 
against a single viral species, for example: hepatitis B virus (HBV), hepatitis C virus (HCV), 
herpesviruses or human immunodeficiency virus (HIV) (3-5), and cross-species antiviral 
activity is rare. BS-AVs could be used to combat several clinically significant and emerging viral 
pathogens when no specific therapies exist (1). Additionally, they could be used as prophylaxis 
in an outbreak setting, to treat chronically infected patients, or when rapid and accurate 
diagnoses are not feasible (6). Given the global health burden created by caliciviruses, there 
is a necessity to develop safe and effective BS-AVs against all Caliciviridae pathogens. 
One strategy in BS-AV development is to target conserved domains of viral enzymes 
critical for replication (1). The viral RNA-dependent RNA polymerase (RdRp) is an attractive 
antiviral target, given its highly-conserved structure across viral families. RdRps are essential 
for viral replication and largely lack host homologs, minimizing chances of off-target effects 
(7). Despite significant sequence diversity, all RdRps form structural homomorphs resembling 
a closed right-hand with fingers, palm and thumb domains (8, 9). To identify broadly 
conserved RdRp regions for further antiviral targeting, bioactive molecules can be identified 
by screening compounds or libraries using polymerase assays with RdRps from several viral 
species (10). This approach can reveal both highly-conserved viral enzyme domains, and BS-
AV candidates with activity against different species, genera and families.  
 
Caliciviruses are a diverse family of positive-sense RNA viruses, currently classified into 
five genera; Norovirus, Sapovirus, Lagovirus, Nebovirus and Vesivirus (11). Viruses from the 
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Caliciviridae cause significant diseases in a wide range of vertebrate hosts (12), and the 
substantial impact caused by caliciviruses is often underestimated (13-15). Currently there 
are no specific antivirals available for the treatment of calicivirus infections, and vaccines are 
only available for two viruses, feline calicivirus (FCV) and rabbit hemorrhagic disease virus 
(RHDV) (16, 17).    
Among the caliciviruses that infect humans, norovirus (NoV) is a leading cause of acute 
gastroenteritis (18, 19), accounting for approximately 219,000 deaths annually (20). Antiviral 
development faces significant challenges, partly because a cell culture system to propagate 
human NoV was only recently established (21, 22). Consequently, much of what is known 
about human NoV biology has been inferred from other caliciviruses including FCV and 
murine norovirus (MNV) (23). Both viruses are easily cultured, and MNV in particular has been 
widely used to screen potential human NoV antivirals in cell culture and mouse models (24). 
Other significant Caliciviridae pathogens include sapovirus (SaV), FCV, and RHDV. SaV 
infects a wide range of species including humans, swine and marine mammals (25), whilst 
RHDV is a highly contagious pathogen that has been used as an effective rabbit biocontrol 
agent (26). Together with benign rabbit calicivirus (RCV), RHDV is a member of the Lagovirus 
genus that infects the European rabbit, Oryctolagus cuniculus (27).  
 
Non-nucleoside inhibitors (NNIs) are antivirals that bind to the RdRp allosterically, 
preventing polymerase conformational changes required for replication (28). All clinically 
approved NNIs to-date offer only narrow-spectrum, species-specific activity, developed 
against either HIV (29) or HCV (30). The HCV RdRp has five defined NNI binding sites (31) 
including: Thumb I (TI), Thumb II (TII), Palm I (PI), Palm II (PII) and Palŵ β ;PβͿ ;Figure ϭAͿ. 
Previously, we reported that HCV TI- and PII-binding NNIs exhibit cross-genotypic activity 
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against HCV (32), indicating the potential for a wider antiviral spectrum. To identify broad-
spectrum calicivirus RdRp targets, we used HCV NNIs as an initial probe for inhibitory activity 
against the human NoV RdRp, and then against a range of caliciviral RdRps.  
Whilst HCV NNI RdRp binding sites are well defined, much less is known about the 
human NoV RdRp. Currently only three human NoV NNI binding sites have been described, 
largely because few NoV NNIs have been reported (33). These three NoV RdRp NNI binding 
sites include one site across the fingers and thumb domains in the RdRp NTP access pathway 
(34, 35), and two binding sites in the thumb domain, named Site-A and Site-B (34).  
Site-A is a positively charged cleft for NTP traversal, with flexible amino acid side 
chains (34). This flexibility poses challenges to structure-based antiviral development; 
therefore Site-A is less attractive than Site-B as an antiviral target site (34).  
Co-crystallization studies of the human NoV RdRp and suramin were used to identify 
its binding pocket in the NTP access pathway between the fingers and thumb domains (35). 
Other examples of compounds that bind in each NNI site include suramin derivatives such as 
NF023 which binds the NTP access pathway (35); naphthalene di-sulfonate (NAF2) which 
binds in Site-A (34); and NAF2 and pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-
disulfonate) tetrasodium salt (PPNDS; Table 1) which both bind in Site-B (34). 
However, suramin and its derivatives, including PPNDS, are poor drug candidates, 
demonstrating cell permeability issues due to the negative charges on the sulfonate groups 
(36, 37), thus limiting bioavailability and antiviral efficacy in viral culture (38). Additionally, 
PPNDS has been eliminated from other studies due to non-specific, off-target activities (39), 
and therefore it lacks the drug-like properties required for further antiviral development. 
PPNDS was first reported as a potent P2X1 receptor agonist (40), but subsequently 
demonstrated potent inhibition of human NoV and MNV RdRps (34, 41) with IC50 values 
Page 7 of 28 
 
between 0.45–0.88 µM (34, 41). Co-crystallization studies with the human NoV RdRp showed 
that PPNDS notably interacts with the Site-B amino acids Q414 and R419, amongst others 
(34). PPNDS reportedly inhibits transcription by fixing the C-terminal end of the RdRp within 
the active site, blocking the incoming RNA template and NTPs (34).  
 
In this study, we aimed to identify broadly-active NNI scaffolds for further antiviral 
development. Representative HCV NNIs were used to probe calicivirus RdRps from the 
Norovirus, Sapovirus and Lagovirus genera for inhibition of transcription. We identified three 
HCV NNIs with pan-Caliciviridae activity. The second aim of this study was to identify highly-
conserved domains across calicivirus RdRps, to target for de novo BS-AV development. Using 
in silico studies and site-directed mutagenesis we identified Site-B as a highly-conserved, 
broad-spectrum calicivirus RdRp pocket, which can now be targeted for antiviral development 
through de novo drug design.  
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2 Materials and Methods  
2.1 Test compounds 
Compounds (Table 1) were purchased from commercial vendors and dissolved in 100% 
dimethyl sulfoxide (DMSO). Compounds: JTK-109 (Dalton, Toronto, Canada), TMC-647055 
and Beclabuvir (BMS-791325; Taizhou Crene Biotechnology, Zhejiang, China), Tegobuvir (GS-
9190) and Nesbuvir (HCV-796; Chemexpress, Shanghai, China), Filibuvir (PF-00868554) and 
Setrobuvir (ANA-598; Acme Biosciences, Palo Alto, CA, USA), Lomibuvir (VX-222; Selleckchem, 
HoustoŶ, TX, USAͿ, Ϯ’-C-methylcytidine (2CMC; Sigma-Aldrich, St. Louis, MO, USA), 3'-
deoxyguanosine-5'-triphosphate ;ϯ’dGTP; TriLiŶk BioteĐhŶologies, SaŶ Diego, CA, USAͿ, 
PPNDS (Molport, Riga, Latvia). 
2.2 Recombinant RdRp expression, purification and mutagenesis 
Recombinant calicivirus RdRps (GenBank accession numbers) NoV GII.4 Den Haag 2006b 
(EF684915), NoV GII.4 Sydney 2012 (KT239579), MNV CW1 (DQ285629), RCV Australia 1 MIC-
07, (EU871528.1), RHDV Czech V351 (KF594473.1), and SaV GI Mc114 (AY237422) were 
expressed and purified as described (42, 43). Mutant RdRps were generated using 
QuikChange site-directed mutagenesis kits (Agilent Technologies, Santa Clara, CA, USA), and 
confirmed by Sanger sequencing.  
2.3 Quantitative RdRp activity and gel-based assays 
Fluorescent activity assays were performed as described (33, 44). GraphPad Prism V6.05 (La 
Jolla, CA, USA) was used to plot the IC50 values. Primed elongation activity was examined as 
in (43), with an RNA template modified from (45), replacing siǆ ϱ’ riďoŶuĐleotides ǁith ϭϬ 
cytidines (PE44-NoV; Figure 3A). Antagonism was calculated using Compusyn software V1.0 
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(46). JTK-109 and PPNDS were tested alone and together (4:1 ratio) against NoV GII.4 Sydney 
2012 RdRp. 
2.4 Inhibition of MNV plaque formation in cell culture  
MNV-1 (CW1) culture assays were performed as described (33). Replication was examined 
using plaque assays (47, 48). Cytotoxicity was examined using CellTitre Blue (Promega, 
Madison, WI, USA) viability assays (33). 
2.5 In silico studies of the JTK-109 binding site  
Molecular docking studies were performed on Viglen Genie Intel®CoreTM i7-3770 vPro CPU@ 
3.40 GHz x 8 running Ubuntu 14.04 using Molecular Operating Environment (MOE) 2015.10 
(49) and Maestro (Schrödinger Release 2016-1) (50) programs as described (51, 52). Briefly, a 
12 Å docking grid was generated using the PPNDS structure (Site-B) as the centroid. The NoV 
RdRp crystal structure bound to PPNDS was downloaded from the Protein Data Bank (PDB) 
(53). Calicivirus RdRps (54) were aligned and superposed using the MOE2015.10 Protein 
Align/Superpose.  
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3 Results  
3.1 HCV TI-binding NNI inhibits human NoV RdRp 
Six HCV NNIs were selected to represent each of the five known HCV allosteric RdRp binding 
sites (Error! Reference source not found.A), including: JTK-109 (TI), Lomibuvir and Filibuvir 
;TIIͿ, Setroďuǀir ;PIͿ, Nesďuǀir ;PIIͿ aŶd Tegoďuǀir ;PβͿ ;Taďle ϭ, Figure ϭAͿ. The iŶhiďitory 
effects of each NNI (0.01 pM – 100 µM) were quantified against human NoV GII.4 RdRp (Den 
Haag 2006b) activity, using a fluorescence-based activity assay (44) (Error! Reference source 
not found.B). Of all the NNIs tested, only the HCV RdRp TI-binder JTK-109 demonstrated 
significant, dose-dependent inhibition of NoV RdRp activity, with an IC50 of 12.6 µM (Error! 
Reference source not found.B).  
3.2 Pan-Caliciviridae antiviral activity of three HCV NNIs 
NoV RdRp inhibition was observed with JTK-109, which binds in the HCV TI pocket (55). 
Therefore, JTK-109 and two other HCV TI-binders currently in clinical trials, namely TMC-
647055 (56) and Beclabuvir (57), were selected for further assessment.   
Using a quantitative fluorescent de novo RdRp assay (33), the synthesis of double-
stranded RNA from an single-stranded RNA polycytidine template was monitored in the 
presence of the three HCV inhibitors (0.1–100 µM). Six RdRps spanning the Norovirus, 
Lagovirus and Sapovirus genera were tested: NoV GII.4 Sydney 2012, NoV GII.4 Den Haag 
2006b, RCV, RHDV, MNV and SaV RdRps (Error! Reference source not found.; RdRp protein 
sequence identity range: 30.2–95.9%). All three HCV TI-binding NNIs demonstrated antiviral 
activity against the calicivirus RdRps. JTK-109 inhibited the six RdRps in a dose-dependent 
fashion, with IC50 values between 4.3 µM (NoV GII.4 Sydney 2012 RdRp) and 16.6 µM (SaV 
RdRp; Error! Reference source not found., Table 2). TMC-647055 also inhibited the activity 
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of all six calicivirus RdRps (IC50 range: 18.8–45.4 µM; Error! Reference source not found., 
Table 2), whilst Beclabuvir demonstrated modest inhibition of NoV and SaV RdRps (IC50 range: 
23.8–92.6 µM), however, was ineffective against the MNV, RCV and RHDV RdRps (IC50 values 
>100 µM; Error! Reference source not found., Table 2).  
3.3 JTK-109 inhibits calicivirus RdRp primed elongation  
As JTK-109 exhibited the most potent broad-spectrum inhibition in the de novo RdRp activity 
assays, it was examined for inhibition of primed-elongation activity using gel-shift assays (58). 
The RNA template [PE44-NoV; modified from (45)] allows primed transcription to extend the 
template from 32 to 44 nucleotides (Figure 3A). Elongation of PE44-NoV by the human NoV 
GII.4 Sydney 2012 RdRp was assessed in the presence of JTK-109 (0.1–100 µM) and the 
nucleoside analogue (NA) ϯ’dGTP (10 µM, Table 1) was used as a positive inhibition control 
(Error! Reference source not found.). In the absence of inhibitors (0.5% DMSO [vol/vol], 
vehicle only), the RNA template was extended, resulting in an upward gel shift (Figure 3). In 
the presence of JTK-109, the product formation was attenuated at 10 µM and almost 
completely abolished at 100 µM (Error! Reference source not found.A). This result is 
consistent with the fluorescence-based NoV RdRp assay results (IC50 4.3 µM, Table 2). Similar 
results were obtained for human NoV GII.4 Den Haag 2006b, MNV, SaV, RCV and RHDV RdRps 
with JTK-109 in the gel-shift assay at a fixed concentration of 100 µM (Figure 3B).    
3.4 JTK-109 inhibits MNV replication in cell culture 
Plaque reduction assays were used to further examine the antiviral activity of JTK-109. 
RAW264.7 cell monolayers were infected with MNV and treated with JTK-109 (0.5–10.0 µM). 
JTK-109 inhibited MNV plaque formation in a dose-dependent manner, with an EC50 of 6.1 
µM (95% CI: 5.1–7.3 µM, Figures 4A, 4D). The NA 2CMC (Table 1) was used as a positive 
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antiviral control, demonstrating complete inhibition of MNV plaque formation at 10.0 µM 
(Figure 4D). JTK-109 had no significant effect on RAW264.7 cell viability within the 
concentration range examined (0.5–10.0 µM; Figure 4B, Figure S1).  
The effects of JTK-109 on MNV viral titers were also examined. JTK-109 concentrations 
ranged from 0.5–10.0 µM and were compared to the vehicle only (negative control). Viral 
titers (PFU/mL) were reduced by JTK-109 treatment (relative to mock) in a step-wise fashion 
(Figure 4C), consistent with the plaque reduction assays.  
3.5 Identification of a BS-AV binding pocket 
The RdRp thumb domain is a highly diverse region in terms of sequence and structure (59) 
between viral families. Therefore, whilst the TI binding pocket for JTK-109 on the HCV RdRp 
is well defined (60), it was uncertain whether it would bind to the same location in calicivirus 
RdRps. In silico studies using superimposition of the two RdRp crystal structures (53, 54, 61), 
revealed that the two alpha-helices present in the HCV RdRp, which form the TI domain, were 
not present in the NoV RdRp. Therefore, the equivalent HCV JTK-109 binding pocket appears 
to be absent in the human NoV polymerase, suggesting JTK-109 binds elsewhere. Moreover, 
molecular docking studies of JTK-109 in the corresponding region of the NoV RdRp also found 
no possible binding sites.  
Further molecular docking of JTK-109 on the NoV GII.4 Sydney 2012 RdRp structure 
identified a potential binding site spanning two previously identified NNI binding sites (Site-A 
and Site-B; Figure 5A) (34). The predicted binding site revealed interactions between JTK-109 
moieties and highly-conserved Site-B amino acids, particularly Q414 and R419.  
To validate the docked model of the JTK-109 binding pocket, we generated two RdRps 
with mutations proposed to be critical for binding, Q414A and R419A, which are both located 
in the Site-B pocket. Transcriptional activity of the mutant RdRps was confirmed, then their 
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relative activity was examined in the presence of JTK-109 (0.1–100 µM; Figure 5B). These data 
supported the in silico study results, as both mutant RdRps were resistant to JTK-109, and 
neither reached 50% inhibition even at 100 µM, compared to an IC50 of 6.3 µM against the 
wildtype RdRp (Figure 5B).  
Representative RdRp structures from the Norovirus, Lagovirus and Sapovirus genera 
were superimposed to reveal that Site-B is a highly-conserved RdRp pocket across the three 
caliciviral genera examined (Figure 5C). Additionally, protein alignments showed Q414 is 
conserved within all calicivirus RdRps examined, while R419 is conserved in the human NoV 
RdRps and is substituted for lysine, another basic amino acid, in all other calicivirus RdRps. 
These two mutations that confer resistance lie within the NoV RdRp thumb domain, but 
neither are located within the functional RdRp motifs, A–G (Figure 5D).   
3.6 PPNDS is antagonistic with JTK-109 and has BS-AV activity against calicivirus RdRps 
As the in silico and mutational studies revealed that JTK-109 binds within the RdRp Site-B, we 
predicted competitive antagonism between JTK-109 and other Site-B binding compounds 
such as PPNDS. Therefore, the inhibitory effects of JTK-109 (0.1–100 µM) and PPNDS (0.025–
25 µM) were examined alone and together (4:1 ratio) against the transcriptional activity of 
the NoV GII.4 Sydney 2012 RdRp (Figure 6A). The average combination index of the NNIs at 
50%, 75% and 90% inhibition was 3.1, confirming the two compounds were antagonistic 
(Figure 6A), indicating that both molecules bind to Site-B. 
As Site-B is conserved within all calicivirus RdRps tested, PPNDS was examined for 
inhibitory activity against the six RdRps using a fluorescent activity assay (0.025–10 µM; Figure 
6B). PPNDS was found to be a potent in vitro transcription inhibitor for all calicivirus RdRps 
(IC50 range: 0.1-2.3 µM, Figure 6B, Table 2). This was confirmed using a gel-shift assay with 
the human NoV GII.4 Sydney 2012 RdRp (0.01–10 µM; Figure 6C), and the RNA template PE44-
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NoV (Figure 3A). PPNDS demonstrated dose-dependent inhibition, almost completely 
abrogating template extension activity at 10 µM. Similar results with PPNDS were obtained 
for human NoV GII.4 Den Haag 2006b, MNV, SaV, RCV and RHDV RdRps in the gel-shift assay 
at a fixed concentration of 10 µM (Figure 6D). However, PPNDS only demonstrated modest 
inhibition of MNV plaque formation in cell culture (20.5% inhibition at 10 µM, Figure 6E), 
demonstrating considerably less potency in cell-based assays compared to the in vitro 
fluorescence (IC50 value: 2.3 µM) and gel-based assays.  
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4 Discussion 
Despite significant research efforts, there are currently no calicivirus-specific antivirals 
available (62). To reduce the global impact of caliciviruses, there is a demand to develop safe 
and effective antiviral therapies (63). BS-AVs are attractive therapeutics, offering the promise 
of a single antiviral to combat several viral pathogens.  
The two major classes of antivirals used to target viral RdRps are NNIs and NAs, with 
NAs already in clinical use as BS-AVs [reviewed in (1)]. Unlike NNIs that bind allosterically, NAs 
mimic incoming NTPs and the RdRp erroneously incorporates them during transcription, 
causing chain termination (64) or lethal mutagenesis (65). This antiviral class includes ribavirin 
(66) which is used to treat several viral infections including respiratory syncytial virus (67) and 
HCV (68). Similarly, Favipiravir is an approved NA for treating influenza patients in Japan (69) 
and is also active against several RNA viruses in mouse models, including Ebola virus (70). In 
addition, 2CMC has been shown in preclinical studies to inhibit the replication of several 
viruses including human NoV (71) and MNV (72), as well as dengue virus, HCV, yellow fever 
virus and West Nile virus (73), amongst others. Moreover, 2CMC is probably the most 
promising and well-studied caliciviral antiviral, with moderate activity demonstrated in MNV 
cell culture (EC50 ~Ϯ μMͿ (72), the NoV replicon (EC50 ϭ8 μMͿ (74) and more recently, in a newly 
developed human NoV culture system (EC50 Ϭ.ϯ μMͿ (75). However, development of 2CMC 
(Valopicitabine) for HCV treatment was halted following reports of undesirable 
gastrointestinal effects, suggesting its use for the treatment of other viruses such as human 
NoV, is unlikely.  
The broad-spectrum antimicrobial compound, Nitazoxanide, has successfully treated 
a single NoV-infected patient (76). Despite reported antiviral activity in vitro against the NoV 
replicon (IC50 1.6  µM), influenza viruses (IC50 range: 0.7 µM – 4.9  µM), HCV genotype 1 (IC50  
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0.3 µM), and HBV (IC50  0.2 µM), amongst other viruses (77), its mode of action is not yet 
understood and further studies are needed. These BS-AVs are largely in the early stages of 
development and currently no calicivirus-specific antivirals are available. 
Numerous antivirals have been developed against HCV, and several FDA-approved 
direct-acting antivirals are now available (30). Therefore, repurposing HCV antivirals should 
be considered for the treatment of other viral infections, or for use in identifying valid antiviral 
targets.  
In this study, we identified three NNIs that bind to the HCV TI pocket, JTK-109, TMC-
647055 and Beclabuvir, which demonstrated dose-dependent RdRp inhibition across the 
three Caliciviridae genera examined. Additionally, JTK-109 exhibited dose-dependent 
inhibition of both primed elongation and de novo RNA synthesis, as well as a reduction of 
MNV plaque formation in cell culture, but demonstrated a low therapeutic index of 4.0.  
There is minimal protein sequence similarity (less than 25%) between NoV and HCV 
RdRps, and the thumb domain is the most diverse region (59). Whilst the HCV RdRp features 
an elaborate thumb domain involved in de novo RNA synthesis, calicivirus RdRps use a 
protein-linked primer and template, thus requiring a wider template-binding channel (59). 
Therefore, calicivirus RdRp thumb domains are smaller and less complex than the equivalent 
HCV RdRp region, and there is no corresponding TI binding pocket present on the NoV RdRp. 
Given these differences, an in silico investigation was used to identify the potential JTK-109 
binding pocket on the human NoV RdRp. Docking studies revealed that JTK-109 binds in the 
NoV thumb domain and predominantly interacts with Site-B, through the conserved amino 
acids Q414 and R419, which was supported by generating drug resistant mutants. Of interest, 
Site-B is the same binding site reported for NAF2 and PPNDS in the human NoV RdRp, and 
both amino acids Q414 and R419 were shown to be involved in their binding (34). PPNDS and 
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JTK-109 were antagonistic in combination, as expected for compounds that occupy the same 
binding site (Site-B) (34). Additionally, overlays of the calicivirus RdRp structures revealed that 
Site-B is highly-conserved within the Caliciviridae, and supporting this analysis, the Site-B 
binder PPNDS was a potent transcription inhibitor in all six calicivirus RdRps examined.  
PPNDS has been reported as an inhibitor of Norovirus RdRp activity (34, 41), and this 
was supported in this study with additional observed inhibition of Lagovirus and Sapovirus 
RdRp transcriptional activities. However, PPNDS was relatively ineffective against MNV 
replication in cell culture. This discrepancy is likely due to its charged phosphate head that 
cannot pass through the cell membrane, which is reflected by the cell permeability issues 
observed with suramin (78) and its other derivatives. Moreover, PPNDS exhibits non-specific 
inhibitory effects (39), and therefore lacks the drug-like properties required for further 
medicinal development. In contrast, several HCV TI-binders have progressed through phase II 
and III clinical trials and could be further developed against other viruses using in silico drug 
design and structure-activity relationship chemistry to improve selectivity, cytotoxicity and 
potency profiles. 
In conclusion, by probing caliciviral RdRps with HCV NNIs we identified three BS-AV 
scaffolds as potential platforms for calicivirus antiviral design. Secondly, we identified that the 
caliciviral RdRp Site-B is a highly-conserved, broad-spectrum target for de novo antiviral 
development. 
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Tables  
Table 1. Antiviral compounds used in this study. 
Compound Structure 
Molecular 
weight (g/mol) 
Inhibitor  
class 
Original 
target 
HCV RdRp 
binding 
site 
Reference 
JTK-109 
 
 
638.1 NNI HCV TI (55) 
TMC-647055 
 
606.7 NNI HCV TI (56) 
Beclabuvir  
(BMS-791325) 
 
659.8 NNI HCV TI (57) 
Lomibuvir  
(VX-222) 
 
 
445.6 NNI HCV TII (79) 
Filibuvir  
(PF868554) 
 
503.6 NNI HCV TII (80) 
Tegobuvir 
 (GS-9190) 
 
517.4 NNI HCV Pβ (81) 
Setrobuvir 
 (ANA-598) 
 
560.6 NNI HCV PI (82) 
Nesbuvir  
(HCV-796) 
 
446.5 NNI HCV PII (83) 
PPNDS 
 
694.3 NNI NoV N/A (34) 
2’-C-Methylcytidine* 
(2CMC) 
 
 
257.2 NA HCV N/A (72) 
3'-deoxyguanosine-
5'-triphosphate* 
;ϯ’dGTPͿ  
507.2 NA 
HCV / 
pestiviruses 
N/A (84) 
* Assay control compounds 
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Table 2. Broad-spectrum activities of NNIs against calicivirus polymerases. 
Virus Family Genus Genotype Strain 
NNI IC50a [µM] in vitro RdRp assay (95% 
CIb) 
JTK-109 TMC-647055 Beclabuvir PPNDS 
NoV Caliciviridae Norovirus GII.4 Sydney 
2012 
4.3 
(2.2-8.5) 
28.3 
(22.7-35.3) 
23.8  
(20.7-27.3) 
1.4  
(1.2-1.7) 
NoV Caliciviridae Norovirus GII.4 Den Haag 
2006b 
10.2 
(9.0-11.7) 
18.8 
(12.7-27.7) 
92.6 
(41.0-209.6) 
0.8 
(0.6-1.0) 
MNV Caliciviridae Norovirus GIV.1 MNV 
CW1 
10.9 
(7.5-15.8) 
23.2 
(15.0-35.8) 
>100 
 
2.3 
(1.8-4.3) 
RHDV Caliciviridae Lagovirus ND Czech  
V-351 
7.6 
(5.9-9.9) 
45.4 
(39.4-52.4) 
>100 
 
0.6 
(0.5-0.7) 
RCV Caliciviridae Lagovirus ND Australia 
1 MIC-07 
15.0 
(12.4-18.1) 
36.5 
(27.8-48.0) 
>100 
 
1.3 
(1.0-1.7) 
SaV Caliciviridae Sapovirus GI Mc114 16.6 
(11.7-23.6) 
37.6 
(29.7-47.7) 
48.6 
(44.2-53.4) 
0.1 
(0.1-0.3) 
HCV Flaviviridae Hepacivirus G1b Con1 / BK 0.02c 0.03d 0.004e N/D 
Grey shading denotes results published previously, outside of this study. 
a IC50: half maximal inhibitory concentration determined by in vitro RdRp assays 
b CI: confidence interval 
c IC50 with HCV genotype 1b BK RdRp (55) 
d IC50 with HCV genotype 1b, Con1 RdRp (56) 
e IC50 with HCV genotype 1b, Con1 RdRp (57) 
 
 
Figure Legends 
Fig. 1. Probing the human NoV RdRp for cross-inhibitory activity with HCV NNIs. A) The HCV 
RdRp domains are color-coded on the ribbon diagram: fingers (red), palm (green), 
thumb (blue) and palm b (yellow). HCV NNI binding sites are shown in colored circles, adapted 
from (Eltahla et al., 2015). B) Inhibitory effects of six HCV NNIs on human NoV GII.4 
Den Haag 2006b RdRp activity were examined using a fluorescence-based RdRp transcription 
assay. NNIs (0.01-100 µM) were compared to samples containing the compound 
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vehicle only (0.5% DMSO [vol/vol]). Mean values from triplicate technical replicates are 
plotted with standard deviations. 
Fig. 2. HCV TI-binding NNIs inhibit calicivirus RdRp activity. The inhibitory effects of three 
HCV TI-binding NNIs were examined on the transcriptional activity of six recombinant 
calicivirus RdRps. The dose-response effects were analysed by monitoring the formation of 
double-stranded RNA from the single-stranded RNA homopolymeric cytidine template, 
using a fluorescent RdRp assay. Compound concentrations ranged between 0.1 and 100 µM 
and RdRp activity was compared to the relative activity of mock treated samples (vehicle 
only). The six panels above include the following RdRps: A) NoV GII.4 Sydney 2012, B) NoV 
GII.4 Den Haag 2006b, C) MNV, D) RCV, E) RHDV and F) SaV. The mean values from 
triplicate datasets from three independent experiments are plotted with standard deviations. 
The half maximal inhibitory concentration (IC50) values for each NNI with the six calicivirus 
RdRps are shown on the graph and in Table 2. 
 
Fig. 3. JTK-109 inhibits calicivirus RdRp primed elongation. A) The effects of JTK-109 on 
human NoV GII.4 Sydney 2012 RdRp primed elongation activity were examined using a 
gel shift assay. PE44-NoV RNA templates (32 nucleotides) were extended (44 nucleotides) by 
the RdRp without JTK-109 (vehicle only) or with JTK-109 (concentration range: 
0.1-100 µM). The nucleoside aŶalogue ϯ’dGTP is used as a positive control (10 µM; Table 1) 
and no RdRp is used as a negative control. B) JTK-109 is assessed at a fixed concentration 
of 100 µM and compared to the effect of DMSO (vehicle only) against human NoV GII.4 Den 
Haag 2006b, MNV, SaV, RCV and RHDV RdRps. Human NoV GII.4 Sydney 2012 is used as a 
positiǀe assaǇ ĐoŶtrol ǁith ϯ’dGTP as the inhibition control (10 µM) to demonstrate total 
inhibition. 
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Fig. 4. JTK-109 inhibits MNV replication in cell culture. Inhibition of MNV plaque formation 
and viral titers was examined using a plaque reduction assay in RAW264.7 cell 
monolayers. A) Total plaque area (mm2) is compared between JTK-109 treated cells (0.5-10 
µM) and mock treated samples (vehicle only). B) JTK-109 has no effect on cell viability at 
concentrations up to 10 µM. C) MNV titers (PFU/mL) are reduced by JTK-109 (0.5-10 µM) in a 
step-wise fashion. Mean values of triplicate technical replicates are plotted with 
standard deviations. D) Plaque area reduction assay results (for panel A) are shown (triplicate 
datasets: black underline), with positive control (2CMC, 10 µM), negative control 
(vehicle only) and JTK-109 (0.5-10 µM). 
 
Fig. 5. Identification of a broad-spectrum NNI binding pocket. A) In silico studies of the JTK-
109 binding site on human NoV GII.4 Sydney 2012 RdRp (using PDB-ID: 4LQ3). RdRp 
domains are color-coded: fingers (red), palm (green), thumb (blue). JTK-109 (cyan structure) 
binds across Site-A (red shadow) and Site-B RdRp (blue shadow). Interacting amino 
acids are color-coded: Q414 (grey sticks, green dotted shadow), R419 (grey sticks, purple 
dotted shadow). B) Relative inhibitory effects of JTK-109 on wildtype NoV GII.4 Sydney 2012 
RdRp activity (blue), compared to mutants Q414A (green) and R419A (purple). The hashed 
red line indicates 50% inhibition compared to mock treated samples (vehicle only) and 
IC50 values are shown on the graph. The mean values of triplicate datasets are shown from 
three independent experiments. C) Superimposition of calicivirus RdRp structures from 
Norovirus (blue, PDB-ID: 4LQ3), Lagovirus (cyan, PDB-ID: 1KHW), Sapovirus (yellow, PDB-ID: 
2CKW) with conserved interacting JTK-109 regions labelled: Q414, R/K419. D) Schematic 
of human NoV RdRp structural domains are color-coded: fingers (red), palm (green), thumb 
(blue), with functional motifs A-G indicated. Asterisks in the thumb domain indicate 
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JTK-109 resistance mutations: Q414A (green) and R419A (purple). 
 
Fig. 6. Antagonism of Site-B binders and pan-Caliciviridae activity of PPNDS. A) Isobologram 
of JTK-109 (0.1-100 µM) and PPNDS (0.025-10 µM) examined in a 4:1 ratio respectively. 
Together both molecules demonstrate antagonism against human NoV GII.4 Sydney 2012 
RdRp activity with an average combination index of 3.1 over 50%, 75% and 90% inhibition. B) 
Inhibitory effects of PPNDS (0.025-10 µM) on calicivirus RdRp activities compared to mock 
treated samples (vehicle only). Mean values from triplicate technical replicates are plotted 
with standard deviations. IC50 values are shown on the graph and in Table 2. C) The effects of 
PPNDS on human NoV GII.4 Sydney 2012 RdRp primed elongation activity were examined 
using a gel shift assay. PE44-NoV (Fig. 3) RNA templates (32 nucleotides) were extended (44 
nucleotides) by the RdRp without PPNDS (vehicle only) or with PPNDS (0.01-10 µM). The 
nucleoside analogue 3'dGTP is used as a positive control (10 µM; Table 1) and no RdRp 
(template only) was used as a negative control. D) PPNDS inhibition of caliciviral RdRp primed 
elongation activity was assessed at a fixed concentration of 10 µM and compared to the effect 
of DMSO (vehicle only) against human NoV GII.4 Den Haag 2006b, MNV, SaV, RCV and RHDV 
RdRps. Human NoV GII.4 Sydney 2012 is used as a positive assay control with 3'dGTP as the 
inhibition control (10 µM) to demonstrate total inhibition. E) The effects of PPNDS on MNV in 
cell culture were examined using a plaque reduction assay. Total plaque area (mm2) is 
compared in the presence of PPNDS (0.1-10 µM) to the vehicle only (negative control) and 
the nucleoside analogue (2CMC, 10 µM, positive control). 
 
Figure S1. The effects of JTK-109 on RAW264.7 cell viability. Cell cytotoxicity of JTK-109 was 
measured with a metabolic resazurin-to-resorufin conversion assay. The percentages of 
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viable cells are shown in the presence of JTK-109 (0.1–100 µM) compared to mock control 
wells containing the compound vehicle only, DMSO (0.5% [vol/vol]). The half maximal 
cytotoxic concentration (CC50) of JTK-109 on RAW264.7 cells was 24.7 µM (95% CI: 23.4–26.1 
µM). The mean values of triplicate technical replicates are plotted with standard deviations. 
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Table	1. Antiviral	compounds	used	in	this	study.
*	Assay	control	compounds
Compound	 Structure	
Molecular	
weight	(g/mol)	
Inhibitor		
class	
Original	
target	
HCV	RdRp	
binding	
site	
Reference	
JTK-109	
	
	
638.1	 NNI	 HCV	 TI	 (55)	
TMC-647055	
	
606.7	 NNI	 HCV	 TI	 (56)	
Beclabuvir		
(BMS-791325)	
	
659.8	 NNI	 HCV	 TI	 (57)	
Lomibuvir		
(VX-222)	
	
	
445.6	 NNI	 HCV	 TII	 (79)	
Filibuvir		
(PF868554)	
	
503.6	 NNI	 HCV	 TII	 (80)	
Tegobuvir	
	(GS-9190)	
	
517.4	 NNI	 HCV	 Pβ	 (81)	
Setrobuvir	
	(ANA-598)	
	
560.6	 NNI	 HCV	 PI	 (82)	
Nesbuvir		
(HCV-796)	
	
446.5	 NNI	 HCV	 PII	 (83)	
PPNDS	
	
694.3	 NNI	 NoV	 N/A	 (34)	
2’-C-Methylcytidine*	
(2CMC)	
	
	
257.2	 NA	 HCV	 N/A	 (72)	
3'-deoxyguanosine-
5'-triphosphate*	
(3’dGTP)	 	
507.2	 NA	
HCV	/	
pestiviruses	
N/A	 (84)	
	
Table	2.	Broad-spectrum	activities	of	NNIs	against	calicivirus	polymerases	in	vitro.
Grey	shading	denotes	results	published	previously,	outside	of	this	study.
a IC50:	half	maximal	inhibitory	concentration	determined	by	in	vitro	RdRp	assays
bCI:	confidence	interval
c	IC50 withHCV	genotype	1b	BK	RdRp	(55)
d IC50 withHCV	genotype	1b,	Con1	RdRp	(56)
e	IC50 withHCV	genotype	1b,	Con1	RdRp	(57)
Virus	 Family	 Genus	 Genotype	 Strain	
NNI	IC50a	[µM]	in	vitro	RdRp	assay	(95%	
CIb)	
JTK-109	 TMC-647055	 Beclabuvir	 PPNDS	
NoV	 Caliciviridae	 Norovirus	 GII.4	 Sydney	
2012	
4.3	
(2.2-8.5)	
28.3	
(22.7-35.3)	
23.8		
(20.7-27.3)	
1.4		
(1.2-1.7)	
NoV	 Caliciviridae	 Norovirus	 GII.4	 Den	Haag	
2006b	
10.2	
(9.0-11.7)	
18.8	
(12.7-27.7)	
92.6	
(41.0-209.6)	
0.8	
(0.6-1.0)	
MNV	 Caliciviridae	 Norovirus	 GIV.1	 MNV	
CW1	
10.9	
(7.5-15.8)	
23.2	
(15.0-35.8)	
>100	
	
2.3	
(1.8-4.3)	
RHDV	 Caliciviridae	 Lagovirus	 ND	 Czech		
V-351	
7.6	
(5.9-9.9)	
45.4	
(39.4-52.4)	
>100	
	
0.6	
(0.5-0.7)	
RCV	 Caliciviridae	 Lagovirus	 ND	 Australia	
1	MIC-07	
15.0	
(12.4-18.1)	
36.5	
(27.8-48.0)	
>100	
	
1.3	
(1.0-1.7)	
SaV	 Caliciviridae	 Sapovirus	 GI	 Mc114	 16.6	
(11.7-23.6)	
37.6	
(29.7-47.7)	
48.6	
(44.2-53.4)	
0.1	
(0.1-0.3)	
HCV	 Flaviviridae	 Hepacivirus	 G1b	 Con1	/	BK	 0.02c	 0.03d	 0.004e	 N/D	
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